Evidence map›Paper›PMID 34976362›Full record

ArticleChemical science2021

How to exploit different endocytosis pathways to allow selective delivery of anticancer drugs to cancer cells over healthy cells.

Vu Thanh Cong, Richard D Tilley, George Sharbeen, Phoebe A Phillips, Katharina Gaus, J Justin Gooding

Abstract read
In one paragraph

Article in Chemical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Golden era of radiosensitizers.Frontiers in veterinary science · 2024
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vu Thanh CongSchool of Chemistry, Australian of NanoMedicine and ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of New South Wales Sydney 2052 Australia justin.gooding@unsw.edu.au.
Richard D TilleySchool of Chemistry, Australian of NanoMedicine and ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of New South Wales Sydney 2052 Australia justin.gooding@unsw.edu.au.ORCID https://orcid.org/0000-0003-2097-063X
George SharbeenPancreatic Cancer Translational Research Group, School of Medical Sciences, Lowy Cancer Research Centre, University of New South Wales Sydney 2052 Australia.ORCID https://orcid.org/0000-0002-6373-1930
Phoebe A PhillipsPancreatic Cancer Translational Research Group, School of Medical Sciences, Lowy Cancer Research Centre, University of New South Wales Sydney 2052 Australia.ORCID https://orcid.org/0000-0002-4481-8782
Katharina GausEMBL Australia Node in Single Molecule Science and ARC Centre of Excellence in Advanced Molecular Imaging, University of New South Wales Sydney 2052 Australia.
J Justin GoodingSchool of Chemistry, Australian of NanoMedicine and ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of New South Wales Sydney 2052 Australia justin.gooding@unsw.edu.au.ORCID https://orcid.org/0000-0002-5398-0597

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It was recently shown that it is possible to exploit the nanoparticle shape to selectively target endocytosis pathways found in cancer and not healthy cells. It is important to understand and compare the endocytosis pathways of nanoparticles in both cancer and healthy cells to restrict the healthy cells from taking up anticancer drugs to help reduce the side effects for patients. Here, the clathrin-mediated endocytosis inhibitor, hydroxychloroquine, and the anticancer drug, doxorubicin, are loaded into the same mesoporous silica nanorods. The use of nanorods was found to restrict the uptake by healthy cells but allowed cancer cells to take up the nanorods

Identifiers

PMID34976362
PMCPMC8635177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.